Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.
about
Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human geneticsRole and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An updateProbiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrityGalectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycleComparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacyThe Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment.Lactobacillus johnsonii ameliorates intestinal, extra-intestinal and systemic pro-inflammatory immune responses following murine Campylobacter jejuni infectionBifidobacterium animalis AHC7 protects against pathogen-induced NF-κB activation in vivo.The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic ScienceIntestinal inflammation responds to microbial tissue load independent of pathogen/non-pathogen discrimination.Bacteriocinogeny in experimental pigs treated with indomethacin and Escherichia coli Nissle.Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.Probiotics, nuclear receptor signaling, and anti-inflammatory pathways.The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition.Disruption of Escherichia coli Nissle 1917 K5 capsule biosynthesis, through loss of distinct kfi genes, modulates interaction with intestinal epithelial cells and impact on cell health.Dextran sodium sulfate-induced inflammation alters the expression of proteins by intestinal Escherichia coli strains in a gnotobiotic mouse model.Enhanced wound healing by recombinant Escherichia coli Nissle 1917 via human epidermal growth factor receptor in human intestinal epithelial cells: therapeutic implication using recombinant probiotics.Goat Milk Yoghurt by Using Lacto-B Culture Modulates the Production of Tumor Necrosis Factor-Alpha and Interleukin-10 in Malnourished Rats.Differential Effects of Escherichia coli Nissle and Lactobacillus rhamnosus Strain GG on Human Rotavirus Binding, Infection, and B Cell Immunity.Quorum sensing in the probiotic bacterium Escherichia coli Nissle 1917 (Mutaflor) - evidence that furanosyl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model.Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity.Biofilm-associated bacterial amyloids dampen inflammation in the gut: oral treatment with curli fibres reduces the severity of hapten-induced colitis in miceProbiotics: properties, examples, and specific applications.Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis.Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation.Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.Probiotic bacteria reduce salmonella typhimurium intestinal colonization by competing for iron.Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases.A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice.Rationale for probiotic treatment strategies in inflammatory bowel disease.The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8.Probiotics and their derivatives as treatments for inflammatory bowel disease.Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway.Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function.Novel immunotherapeutic approaches for allergy and asthma.Role of Toll-like receptors in the development of immunotolerance mediated by probiotics.Amelioration of intestinal and systemic sequelae of murine Campylobacter jejuni infection by probiotic VSL#3 treatment.
P2860
Q21131205-AE887B96-797A-46CB-BADD-4C4749E67A53Q26746916-28AA9508-C520-4CD6-9120-3995C426AC97Q33309955-6E3DCD78-E68D-414D-AC6D-85F1E3289B8BQ33350222-7CE41BA5-C2E8-4B51-B36C-79A121F5E8F7Q33503647-4ECF4BF7-9E1A-4174-B4EB-C22B997C2A9BQ33639134-70A12A09-1B3D-4A2C-BAC5-C633D7A33F4FQ33705072-EEB556FA-CAD8-4CE7-87E7-7851120C8AF9Q33777570-B60E539F-7FCD-43C6-8249-E588A0D5B10DQ33864337-5A39129F-CDA8-4E74-A7A9-29746EE0AC4FQ34162963-66382181-705B-4D1D-B767-020EEAB509A0Q34269047-A527CD6F-B793-4F46-8957-E98D5BA1905FQ34579758-B55AA641-66E2-405D-9049-602A77BA4B7BQ34588415-2E7C7E45-83BC-4868-9E52-79418EE38903Q34637606-5C750CCD-B689-4BCD-89BD-37A42E66623EQ34744012-F25C047F-805C-4B45-BB6E-41E423F0082AQ35131051-29A87E15-F6F7-4AC0-BB8D-66D0AA3827A7Q35571641-6A083F98-1280-4EFF-A12A-63E98DE0B000Q35581546-8B06C037-A08E-4D6B-9D82-37D744AEA1B7Q35804807-071485E6-482F-4FA1-A547-839D1D71637DQ35805420-74FC52B7-700C-4C5D-9C45-6963581D53E5Q35892618-77885341-99F1-46FC-9FAF-A6A8167030CBQ35901914-45E97FB1-5648-4D86-A23C-DE4371893872Q36346261-690637D3-BFBB-4E37-9E82-3B813C0ABC29Q36392065-49716C60-117E-4EB5-AF8D-15FAB5786E42Q36539870-2C8908CD-0DBD-4C7C-BA09-1F6EF4ED1383Q36629073-B925CE06-12E4-4C8E-B601-01F51F88FCF0Q36669223-ACC931B5-209A-4007-88D7-B4C2E459240AQ36809889-569ADCC6-6AE2-4A04-8B8B-9F5BDDEC2F4DQ37082773-92B5A299-C0AF-4676-B79D-7E70FE3831CBQ37118020-4D9CB26E-639D-422D-B916-F23B821963DDQ37214848-A9BB5B33-F255-4A07-BF41-E022392EEB70Q37332655-19EBF9EC-67B7-4000-B9B6-4E0A0B6CFD87Q37345932-66DC92C5-3A07-42C1-9418-B1909B3BD382Q37421164-FF2F6C01-DAC5-4652-B53E-4AF0B0A95954Q37448522-CAEBF4E6-60CD-41A4-8976-50A92F3E3A31Q37575684-717DB093-8698-44A9-BEA0-81C08DAE72ADQ37642855-40C29471-8468-48F6-8C9D-49191A5A31C9Q37728000-8F8680DA-16E8-4E4D-A29B-E9B8B27C820DQ37736645-61463B45-3C8A-4B59-B2A0-F572D6E1CC3BQ37748061-84006E2B-2CC8-4A36-8021-728AB7539E43
P2860
Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Escherichia coli strain Nissle ...... receptor 4-dependent pathways.
@en
type
label
Escherichia coli strain Nissle ...... receptor 4-dependent pathways.
@en
prefLabel
Escherichia coli strain Nissle ...... receptor 4-dependent pathways.
@en
P2093
P2860
P356
P1476
Escherichia coli strain Nissle ...... receptor 4-dependent pathways.
@en
P2093
A U Dignass
B Wiedenmann
D C Baumgart
P2860
P304
P356
10.1128/IAI.01449-05
P407
P577
2006-07-01T00:00:00Z